FDAnews/CenterWatch Announces -- Real World Evidence and Data: A Tufts Study of 30 Pharma Companies Webinar January 23, 2020

Using real world evidence in the next trial? Gain insights in support of development and post-approval safety studies.

News provided by

CenterWatch

Jan 09, 2020, 00:00 ET

FALLS CHURCH, Va., Jan. 9, 2020 /PRNewswire-PRWeb/ -- Real World Evidence and Data:
A Tufts Study of 30 Pharma Companies
An FDAnews/CenterWatch Webinar
Thursday, Jan. 23, 2020 • 1:30-3:00 p.m. EST
https://www.centerwatch.com/rweanddata

How can one use real world evidence (RWE) and real world data (RWD) to generate evidence and identify gaps and challenges when conducting trials? The Tufts Center for the Study of Drug Development (CSDD) recent case studies can provide valuable insights.

The CSDD investigated 30 biopharmaceutical companies use of RWD to generate evidence and showed the top measures for using RWE for return on investment, among other factors. It concluded that expanding the use of RWE in regulatory decisionmaking and increasing sponsors' use of RWD will fill critical gaps related to drug development and safety. The speakers will walk attendees through the study's important takeaways.

Mary Jo Lamberti, PhD, a Tufts University professor and associate director of sponsored research at the CSDD, along with Francis Kendall, a 30-year pharmaceutical industry veteran and senior director at Cytel where he is an instrumental player in the company's Real World Analytics team, will discuss cases of what is being done with RWE and RWD:

  • Types of technology used to access or collect RWD and evidence
  • Significant challenges to using RWD
  • Strategies and practices that impact return on investment or performance
  • Key drivers for change and the adoption of RWE
  • The potential of RWE and how it may be used across the clinical development pipeline
  • A view on what will happen next in the RWE domain

Understand the critical factors you need to consider in using RWE and gain insight into the current and planned uses of RWE to support development and post-approval safety studies.

Interested in registering multiple sites?
Call (888) 838-5578 in the U.S. or +1 (703) 538-7600 globally
to learn about our special multisite discount.

Webinar Details:
Real World Evidence and Data:
A Tufts Study of 30 Pharma Companies
An FDAnews/CenterWatch Webinar
Thursday, Jan. 23, 2020 • 1:30-3:00 p.m. EST
https://www.centerwatch.com/rweanddata

Tuition:
$287 per site
Easy Ways to Register:
Online: https://www.centerwatch.com/rweanddata
By phone: 888-838-5578 or 703-538-7600

About FDAnews:
FDAnews is the premier provider of domestic and international regulatory, legislative,
and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on FDAnews' print and electronic newsletters, books and conferences to stay in compliance with international standards and the FDA's complex and ever-changing regulations.

About CenterWatch:
Founded in 1994, CenterWatch is a trusted source and global destination for clinical trials information for both professionals and patients. CenterWatch provides proprietary data and information analysis on clinical trials through a variety of newsletters, books, databases, and information services used by pharmaceutical and biotechnology companies, CROs, SMOs, and investigative sites involved in the management and conduct of clinical trials. As a pioneer in publishing clinical trials information, CenterWatch was the first Internet site to publish detailed information about active clinical trials that could be accessed by patients and their advocates.

SOURCE CenterWatch